RenovoRx Ownership
| RNXT Stock | USD 0.97 0.02 2.02% |
RenovoRx |
RenovoRx Stock Ownership Analysis
The book value of the company was at this time reported as 0.3. The company recorded a loss per share of 0.58. RenovoRx had not issued any dividends in recent years. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To find out more about RenovoRx contact Shaun Bagai at 650 284 4433 or learn more at https://renovorx.com.Besides selling stocks to institutional investors, RenovoRx also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different RenovoRx's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align RenovoRx's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
RenovoRx Quarterly Liabilities And Stockholders Equity |
|
Only 1.28% of RenovoRx are currently held by insiders. Unlike RenovoRx's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against RenovoRx's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of RenovoRx's insider trades
RenovoRx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as RenovoRx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading RenovoRx backward and forwards among themselves. RenovoRx's institutional investor refers to the entity that pools money to purchase RenovoRx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 12.3 K | Two Sigma Securities, Llc | 2024-12-31 | 11.7 K | Tower Research Capital Llc | 2024-12-31 | 817 | Citigroup Inc | 300000-12-31 | 384 | Bank Of America Corp | 2024-12-31 | 196 | Family Firm Inc | 2024-09-30 | 0.0 | Blackrock Inc | 2024-09-30 | 0.0 | Bank Of Montreal | 3000-12-31 | 0.0 | Bmo Capital Markets Corp. | 2024-12-31 | 0.0 | Adar1 Capital Management Llc | 2024-09-30 | 315.2 K | Geode Capital Management, Llc | 2024-12-31 | 235.7 K |
RenovoRx Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RenovoRx insiders, such as employees or executives, is commonly permitted as long as it does not rely on RenovoRx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RenovoRx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RenovoRx Outstanding Bonds
RenovoRx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RenovoRx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RenovoRx bonds can be classified according to their maturity, which is the date when RenovoRx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.